報價延遲最少15分鐘:2025/03/12 22:33 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.55 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.88/-1.98
|
|
企業價值
414.85M
|
| 資產負債 |
|
每股賬面淨值
26.94
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/12 22:33 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency. |